|1/11/13||California Pharmaceutical Company Acquires Biotech (Wealth Daily)|
BioMarin (NASDAQ: BMRN) has acquired Zacharon Pharmaceuticals to help with genetic disease drug research.
|8/7/12||Dimon’s JPMorgan Stock Purchase Aims To Put Investors At Ease (Phil’s Stock World)|
Courtesy of Benzinga. BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that on July 16, 2012, the compensation committee of BioMarin's board of directors approved the grant to two employees of stock options to purchase 13,400 shares of common stock in the aggregate [...]
|8/7/12||BioMarin Pharmaceutical Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Phil’s Stock World)|
Courtesy of Benzinga. NuPathe Inc. (NASDAQ: PATH), today announced that it has granted time-based stock options to Armando Anido, the Company's newly appointed chief executive officer, pursuant to the NASDAQ inducement grant exception. The inducement grants were approved by the Company's board [...]
|12/14/11||(BMRN) BioMarin Pharmaceutical Reports Pipeline Progress (Stock Blog Hub)|
Recently, BioMarin Pharmaceutical Inc. (BMRN) commenced a mid-stage study of its pipeline candidate GALNS (N-acetylgalactosamine 6-sulfatase) in children suffering from mucopolysaccharidosis IVA (MPS IVA), a rare genetic enzyme deficiency disorder. The company intends to evaluate the safety and tolerability of the drug dosed at 2.0 mg/kg/week over a period of one year. The study will evaluate [...]
|9/29/11||標普或測試8月低點1100點 (Capital Essence's Investment Blog- 錢途集團 » Page not found)|
|6/29/11||(BMRN) BioMarin Pharmaceutical to Buy Pfizer Plant (Stock Blog Hub)|
BioMarin Pharmaceutical Inc. (BMRN) recently announced that it will acquire an integrated biologics manufacturing plant from pharma giant Pfizer Inc. (PFE) which will expand its manufacturing capacity to manage its proliferating product portfolio and its maturing pipeline. The plant, for which BioMarin will pay $48.5 million, is located in Shanbally, Cork, Ireland and is spread across [...]
|6/19/11||8 Potential Biotech Acquisition Candidates (Investment Underground » Page not found)|
Here are 8 promising biotechs priced for a buyout if their products can deliver: BioMarin Pharmaceutical Inc. (BMRN): It's not the most profitable company, but BioMarin Pharmaceuticals certainly has some promising products in its portfolio. The company first achieved profitability in 2008, and its two largest revenue drivers in 2010 were Naglazyme (14% growth to $193 million) [...]
|4/27/11||(BMRN) BioMarin Pharmaceutical – Bear of the Day (Stock Blog Hub)|
We are downgrading BioMarin Pharmaceutical Inc. (BMRN) to Underperform from Neutral following the below-par showing of the company in the final quarter of 2010. Earnings were hurt by lower-than-expected revenues. We were disappointed with the continued weak performance of Aldurazyme and the slow Firdapse ramp. Moreover, we expect cash burn to increase since the company is [...]
|4/9/11||(MYGN) Myriad Genetics and BioMarin Pharmaceuticals Enter Agreement for Testing (Stock Blog Hub)|
Myriad Genetics (MYGN) has entered into an agreement with BioMarin Pharmaceuticals (BMRN) to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in the latter’s phase I/II clinical study of BMN 673. BMN 673 is a PARP-inhibitor drug candidate for treatment of genetically defined cancers. Bracanalysisis Myriad’s flagship product, contributing 89% of total revenue. [...]
|2/22/11||NASDAQ Healthcare Sector Losers: (BMRN, DEPO, BPAX, ZLCS, ARAY) (Penny Stock DD)|
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) moved down by 3.75% and closed at $27.23 whereas overall traded volume stood at 2.84 million shares for the day. The current market price is 2.01% more than its last 50 days simple moving average. The relative strength index stands at 56.64 times till its last trading session. DepoMed, Inc. (NASDAQ:DEPO) went [...]
|10/28/10||BioMarin Announces Third Quarter 2010 Financial Results: EPS of 1.74 (Benzinga)|
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced financial results for the third quarter of 2010. GAAP net income was $217.3 million ($1.68 per diluted share) for the third quarter of 2010, compared to GAAP net income of $6.6 million ($0.07 per diluted share) for the third quarter of 2009. Non-GAAP net income was $6.0 million ($0.06 per diluted share) for the third quarter of 2010, compared to non-GAAP net income of $15.5 million ($0.14 per diluted share) for the third quarter of...
|10/20/10||J.P. Morgan Reiterates Overweight On BioMarin (BMRN) (Benzinga)|
J.P. Morgan Chase & Co. is reiterating its Overweight rating on price target BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), after the company held an R&D yesterday in New York. It has a $28 price target on shares. In a note to clients, J.P. Morgan writes, "R&D spend will increase to a hefty $200M in 2011. Based on conversations with investors, we don't believe this development comes as a big surprise even though it appears to be well ahead of Street forecasts (our prior 2011 assumption was...
|10/19/10||BioMarin Announces Program for BMN-111 (Benzinga)|
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced its program for BMN-111, a peptide therapeutic for the treatment of achondroplasia. BioMarin plans to file an IND in the fourth quarter of 2011 and to initiate a Phase 1 clinical trial by the first quarter of 2012. BMN-111, for the treatment of achondroplasia, is an analog of C-type Natriuretic Peptide (CNP), a small cyclic peptide that is a positive regulator of bone growth. It is produced and has a receptor in the growth plate,...
|4/22/10||(BMRN) BioMarin Pharma Announces Good News (Stock Blog Hub)|
BioMarin Pharma Inc. (BMRN) announced recently that its product Firdapse (Amifampridine phosphate) for treating Lambert Eaton Myasthenic Syndrome (LEMS) is commercially available in the European Union. While the company has launched the product in Germany and the UK subsequent launches in other major European markets are expected by the end of the year. The LEMS drug [...]
|3/25/10||Board member resignation at Biomarin raises questions, among them a possible buyout (BMRN) (AlphaNinja)|
(first reported at footnoted.org) Biomarin (BMRN) released some back-and-forth between the company and resigning board member Joseph Klein. In his resignation letter , Klein claims his efforts were unappreciated, especially in regards to internal audit investigations and dealings with management. The market is sending shares higher today on buyout speculation, but what caught my interest was the disagreements over depreciation timetables. There exists disagreement between the...
|2/24/10||(BMRN) BioMarin Pharmaceutical’s Earnings Top Analyst Estimates (Stock Blog Hub)|
BioMarin Pharmaceutical Inc. (BMRN) reported fourth-quarter 2009 earnings of 13 cents per share (excluding special items), beating the Zacks Consensus Estimate of break-even earnings. The company had earned 8 cents (excluding special items) in the year-ago quarter. Quarterly Results Revenue for the reported quarter came in at $87.1 million as against $99.3 million in the comparable quarter [...]
|2/9/10||(BMRN) BioMarin Pharmaceutical Announces Plan to Expand (Stock Blog Hub)|
BioMarin Pharmaceutical Inc. (BMRN) announced recently that it will purchase the privately-held drug discovery and early stage development company LEAD Therapeutics. LEAD is developing LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for treating patients suffering from rare, genetically defined cancers. The stock purchase agreement requires BioMarin to make an upfront payment of $18 [...]
|1/6/10||(BMRN) BioMarin Pharma’s Drug Cleared in Europe (Stock Blog Hub)|
BioMarin Pharma Inc. (BMRN) announced recently that its drug candidate 3, 4-diaminopyridine amifampridine phosphate (3,4-DAP), indicated for treating Lambert Eaton Myasthenic Syndrome (LEMS), has received marketing approval from the European Commission. In October 2009, the Committee for Medicinal Products for Human Use of the European Medicines Evaluations Agency gave a positive opinion and recommended the [...]
|12/2/09||(BMRN) BioMarin Pharmaceutical Earns Orphan Status From FDA (Stock Blog Hub)|
Recently, BioMarin Pharmaceutical Inc. (BMRN) announced that the U.S. Food and Drug Administration (FDA) granted orphan drug status to its candidate 3,4-diaminopyridine amifampridine phosphate (3,4-DAP), for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). As a reminder, BioMarin acquired the privately held Huxley Pharmaceuticals Inc. last month which possessed rights to a proprietary form of 3, [...]
|10/27/09||(BMRN) BioMarin Pharmaceutical Purchases Huxley Pharmaceuticals (Stock Blog Hub)|
Recently, BioMarin Pharmaceutical Inc. (BMRN) announced that it has acquired the privately held Huxley Pharmaceuticals Inc., which possessed rights to a proprietary form of 3,4-diaminopyridine amifampridine phosphate ( 3,4-DAP), for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Under the terms of the transaction, BioMarin has already made an upfront payment of $15 million to Huxley [...]
|9/23/09||(BMRN) BioMarin Pharmaceutical Begins Mid-Stage Trial (Stock Blog Hub)|
Yesterday, BioMarin Pharmaceutical Inc. (BMRN) said it started a mid-stage study of PEG-PAL for the treatment of phenylketonuria (PKU). The company expects initial results from the study in mid-2010. It is co-developing the candidate with Merck Serono (MRK). The primary objective of the open-label, multi-center study, to be conducted in up to 35 patients, is to [...]